Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis
详细信息 查看全文
- 作者：Changlin Mei ; Nan Chen ; Xiaoqiang Ding ; Xueqing Yu ; Li Wang ; Jiaqi Qian ; Mei Wang ; Gengru Jiang ; Xuemei Li ; Fanfan Hou ; Li Zuo ; Niansong Wang and Hong Liu
- 刊名：Hemodialysis International
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：20
- 期：4
- 页码：589-600
- 全文大小：442K
- ISSN：1542-4758
文摘
Introduction Secondary hyperparathyroidism (SHPT) develops in patients with chronic renal failure. Cinacalcet hydrochloride has been used successfully in U.S., Europe, and Japan in the treatment of SHPT, while maintaining serum levels of calcium and phosphorus. The efficacy and safety profile of Cinacalcet treatment vs. conventional treatments has been of great interest in clinical practice. In this recent phase III study conducted in China, efficacy and safety of a calcimimetic agent, Cinacalcet (Kyowa Hakko Kirin Co., Ltd.), were assessed for SHPT treatment in stable chronic renal disease patients on hemodialysis.